Meet with our Cancer Researchers
You are invited to the next CureCancer Technology, Innovation & Medicine (TIM) bit Tuesday at NANUC on Tuesday December 5, 2017. We will focus on new developments in prostate cancer detection and treatment.
Please share the POSTER.
Register for Free: share your thoughts, hear short engaging talks by scientists and clinical researchers studying how cancer develops and can be tackled more effectively.
TIM bit Tuesday Meet & Greet (5:30 pm)
Join us for an informal discussion about our cancer research on first Tuesdays of every quarter. Food and drinks provided.
TIM bit Tuesday Talks (6 pm)
Hear about cancer research from cancer researchers discovering how to understand, detect and treat breast cancer better.
Speakers include:Catalina Vasquez, Program Director, APCaRI, Department of Oncology, University of Alberta, coordinates the Alberta Prostate Cancer Cohort for developing diagnostic tests, and will speak about Prostate Cancer Research in Alberta: interlocking stories with an impactful end in mind.
Justin Bailey, Research Associate at the University of Alberta's Medical Isotope and Cyclotron Facility and Department of Oncology, works with Professor Ralf Schirrmacher on developing new imaging agents for oncology including nanoparticles and radionuclides.
Nawaid Usmani, Radiation Oncologist and Associate Professor, Department of Oncology, University of Alberta, focuses on prostate brachytherapy, which is an increasingly popular treatment option for localized prostate cancer. He will speak on Prostate brachytherapy: Treating patients with radioactive pellets.
TIM bit Tuesday Tour (7 pm)
Take a guided tour of a lab to see where scientists are discovering how cancer forms and how new treatments are being developed.Register now as our events fill up (no cost or obligation).
TIM bit Tuesday speakers on September 5, 2017:
Lynne Postovit studies how cells develop into tumours in response to cues in their local microenvironment.
Co-director, Cancer Research Institute of Northern Alberta and Professor, Department of Oncology
Faculty of Medicine & Dentistry
Tina Rinker directs the Centre for Bioengineering Research and Education at the University of Calgary, and founded Syantra Diagnostics and KRS Biopharma to detect breast cancer earlier and improve outcomes.
Larry Fliegel studies how breast cancer cells grow, invade and metastasize due to altered proteins that control acid levels. He is a member of CRINA and the Membrane Group, and a Professor, Department of Biochemistry in the Faculty of Medicine & Dentistry
TIM bit Tuesday speakers on March 7, 2017:
Ashlee Matkin is developing new ways to detect cancer in thyroid nodules.
Nasim Danaei is tackling a new kinase target involved in triple negative breast cancer.
Matthew Benesch is discovering biomarkers and autoinflammatory agents for cancer treatment.
TIM bit Tuesday speakers on December 6, 2016:
Cameron Smithers, PhD student studying a new prostate cancer target using drug fragments and research magnets.
Lian Willetts, Post-doctoral Fellow exploring signaling pathways and identifying drivers for human cancer metastasis.
Kausar Saboohi, Scientist developing molecular libraries and protein thermal shift assays to stabilize and exploit drug targets.
TIM bit Tuesday speakers on September 6, 2016:
Steffane McLennan was awarded her Bachelor of Science (Honors) in Biochemistry in 2016 from the University of Alberta. She is plans to find new ways using drug fragments to inhibit an oncogenic kinase that causes triple negative breast cancer.
Frodo Bark is an undergraduate student at the University of Alberta in the Faculty of Science who is studying how the Fyn signaling protein interacts with cell surface lipids and receptors to regulate growth thanks to support from NACTRC.
Sonya Soh is an undergraduate student pursuing a Bachelor of Science (Honours) in Biochemistry at the University of Alberta. She is studying the phosphatase SHP2, and is using structure-based methods to investigate the effects of mutations including those responsible for its hyperactivity in leukemia.
Anna Jutla is finishing her undergraduate studies in the Faculty of Science majoring in Chemistry. She is working with Dr. Michael Overduin as a summer student on an oncogenic phosphatase, SHP2, and is using an array of biophysical methods to assess binding affinities between the enzyme and drug-like molecules.